
    
      This single-centre, open-labeled randomized controlled study will evaluate the safety and
      efficacy of adalimumab in etanercept-treated Ankylosing Spondylitis(AS) patients.

      Thirty patients will be enrolled and randomized equally into two arms.

      Dosage and Administrationï¼šFor standard dose(etanercept 50 mg weekly) treated patients, the
      treatment arm will receive adalimumab 40 mg subcutaneously biweekly for 8 weeks. The control
      arm will continue etanercept 25 mg subcutaneously twice a week for 8 weeks. At week 8, the
      control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8
      weeks.For half dose(etanercept 25 mg weekly) treated patients, the treatment arm will receive
      adalimumab 40 mg subcutaneously monthly for 8 weeks. The control arm will continue etanercept
      25 mg subcutaneously weekly for 8 weeks. At week 8, the control arm will be switched to
      adalimumab 40 mg subcutaneously monthly for another 8 weeks.
    
  